These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32516282)

  • 21. Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes.
    Hirotsu N; Sakaguchi H; Sato C; Ishibashi T; Baba K; Omoto S; Shishido T; Tsuchiya K; Hayden FG; Uehara T; Watanabe A
    Clin Infect Dis; 2020 Aug; 71(4):971-981. PubMed ID: 31538644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
    Abraham GM; Morton JB; Saravolatz LD
    Clin Infect Dis; 2020 Oct; 71(7):1790-1794. PubMed ID: 32020174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza Season.
    Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Hashimoto K; Hosoya M
    J Infect Dis; 2020 Jun; 222(1):121-125. PubMed ID: 32034420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].
    Taieb V; Ikeoka H; Ma F; Borkowska K; Aballea S; Tone K; Hirotsu N
    Ter Arkh; 2020 Dec; 92(11):122-131. PubMed ID: 33720617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
    Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
    BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
    Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus.
    Baba K; Oka R; Shano S; Omoto S; Noshi T; Shishido T; Naito A; Kawaguchi K; Ishibashi T; Uehara T
    Influenza Other Respir Viruses; 2020 May; 14(3):353-357. PubMed ID: 31994309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baloxavir (Xofluza) for post-exposure prophylaxis of influenza.
    Med Lett Drugs Ther; 2021 Jan; 63(1615):2-3. PubMed ID: 33646997
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial.
    Ikematsu H; Baba T; Saito MM; Kinoshita M; Miyazawa S; Hata A; Nakano S; Kitanishi Y; Hayden FG
    Influenza Other Respir Viruses; 2024 May; 18(5):e13302. PubMed ID: 38706384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.
    Shiraishi C; Kato H; Hagihara M; Asai N; Iwamoto T; Mikamo H
    J Infect Chemother; 2024 Mar; 30(3):242-249. PubMed ID: 37866622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Shirley M
    Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study.
    Baker JB; Block SL; Cagas SE; Macutkiewicz LB; Collins C; Sadeghi M; Sarkar S; Williams S
    Pediatr Infect Dis J; 2023 Nov; 42(11):983-989. PubMed ID: 37595103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Ogura E; Fujiwara M; Miyauchi H; Ajisawa Y; Iwata S; Watanabe H; Honda K; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Jun; 72(11):e859-e867. PubMed ID: 33103200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of baloxavir marboxil prescription with subsequent medical resource utilization among school-aged children with influenza.
    Takeuchi M; Kawakami K
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):779-786. PubMed ID: 33608939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
    Takashita E; Kawakami C; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T;
    Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baloxavir treatment of oseltamivir-resistant influenza A/H1pdm09 in two immunocompromised patients.
    Macesic N; Laplante JM; Aaron JG; DiMango EA; Miko BA; Pereira MR; Reshef R; St George K
    Transpl Infect Dis; 2021 Jun; 23(3):e13542. PubMed ID: 33278052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.
    Sonoyama T; Sakaguchi H; Koshimichi H; Noshi T; Tsuchiya K; Uehara T
    J Infect Chemother; 2021 Aug; 27(8):1223-1229. PubMed ID: 34045119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.